SEC Form 4 · accession 0001144204-17-009645
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John N Braca
Director
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Company Stock OptionF1 | $0.22 | Feb 14, 2017 | A | 167,045 | A | Feb 14, 2017 | Feb 14, 2027 | Common Stock | 167,045 | 167,045 | D |
Explanation of responses
- F1Such options were granted to Mr. Braca in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.